LEXINGTON, Mass., Nov. 3, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ), a company developing innovative diagnostic products to improve patient health, today announced the appointment of veteran healthcare commercialization executive, David P. Harding, as the Company's chief commercial officer (CCO), effective immediately.
"With multiple development programs moving toward clinical trials, international expansion on the horizon, and continued rapid sales growth planned in the United States, I am pleased to announce the appointment of David P. Harding to the role of chief commercial officer," said John McDonough, chief executive officer of T2 Biosystems. "David's skill-set and extensive experience will further enhance our ability to build and lead an integrated global commercial business with multiple technologies and scale those businesses. We look forward to working with David."
Prior to joining the company, Harding was CCO of Ovascience, Inc., a global fertility company, where he oversaw the sales and marketing functions for the company during the early stages of commercialization. Prior to that role, Harding held several roles with Hologic, Inc., a global healthcare and diagnostics company. His most recent role was group senior vice president and general manager where he managed global sales and marketing and re-structured the team's research and development portfolio. Harding also held executive roles with Cytyc Corporation and McKinsey and Company, Inc.
Harding earned his M.B.A. from The Wharton School, University of Pennsylvania and his B.S. in aerospace engineering from the University of Southern California.
"It's exciting to join a company developing leading technologies in the field of in vitro diagnostics with a breadth of robust, novel products in the pipeline," explained Harding. "With the FDA-approved T2Candida Panel already on the market and multiple new products heading into the clinic, 2016 will be a productive year of continued commercial growth for the Company and I'm proud to join such an innovative team."
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR ® , to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established. For more information, please visit www.t2biosystems.com .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2014, as supplemented or amended from time to time under "Item 1A.—Risk Factors" in our Quarterly Reports on Form 10-Q, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release .
Media Contact: Susan Heins, Pure Communications 864.286.9597 Investor Contact: Matt Clawson, Pure Communications 949-370-8500
